SECURITIES AND EXCHANGE COMMISSIONSEC FORM 17-C

CURRENT REPORT UNDER SECTION 17
OF THE SECURITIES REGULATION CODE
AND SRC RULE 17.2(c) THEREUNDER

1. Date of Report (Date of earliest event reported)

Oct 1, 2026

2. SEC Identification Number

168063

3. BIR Tax Identification No.

000-065-142-000

4. Exact name of issuer as specified in its charter

PRYCE CORPORATION

5. Province, country or other jurisdiction of incorporation

Philippines

6. Industry Classification Code(SEC Use Only)

7. Address of principal office

17F Pryce Center 1179 Don Chino Roces Ave. corner Bagtikan Street, Makati City Postal Code 1203

8. Issuer's telephone number, including area code

(+632) 8899 4401

9. Former name or former address, if changed since last report

-

10. Securities registered pursuant to Sections 8 and 12 of the SRC or Sections 4 and 8 of the RSA

Title of Each Class	Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
Common	1,880,546,169
Treasury	143,953,831

11. Indicate the item numbers reported herein

Item 9

The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.

Pryce CorporationPPC

PSE Disclosure Form 4-2 - Acquisition/Disposition of Shares of Another Corporation
References: SRC Rule 17 (SEC Form 17-C) and
Section 4.4 of the Revised Disclosure Rules

Subject of the Disclosure
PRYCE CORPORATION REMOVES PHARMACEUTICAL BUSINESS
Background/Description of the Disclosure
Please see the attached disclosure entitled: "PRYCE CORPORATION REMOVES PHARMACEUTICAL BUSINESS".

Date of Approval by Board of Directors	Sep 30, 2026

Rationale for the transaction including the benefits which are expected to be accrued to the Issuer as a result of the transaction
Pryce Corporation seeks to streamline its business operations by removing its auxiliary segments, which necessarily include the pharmaceutical product arm.

Details of the acquisition or disposition

Date	Sep 30, 2026

Manner
Deed of Assignment and Transfer of Shares
Description of the company to be acquired or sold
Pryce Pharmaceuticals Inc. is a domestic corporation which is a subsidiary of Pryce Corporation, with registered business address at LGF Skyland Plaza, cor. Gil Puyat Avenue and Tindalo St., San Antonio, Makati City. Its primary purpose is to engage in the business of trading goods such as pharmaceutical products on wholesale and retail basis.

The terms and conditions of the transaction

Number of shares to be acquired or disposed	7,500,000
Percentage to the total outstanding shares of the company subject of the transaction	75
Price per share	1.00

Nature and amount of consideration given or received
The consideration for the assignment and transfer of shares will be at Seven Million Five Hundred Thousand Pesos (Php 7,500,000.00), payable in cash.
Principle followed in determining the amount of consideration
Consideration is based on par value under Pryce Pharmaceuticals Inc.'s Articles of Incorporation.
Terms of payment
The total amount of consideration will be paid in cash within a period of seven (7) calendar days.
Conditions precedent to closing of the transaction, if any
None.
Any other salient terms
None.

Identity of the person(s) from whom the shares were acquired or to whom they were sold

Name	Nature of any material relationship with the Issuer, their directors/ officers, or any of their affiliates
PGI Retirement Fund Inc.	Three of the Issuer

Effect(s) on the business, financial condition and operations of the Issuer, if any
The Issuer's remaining business segments after the transaction will include liquefied petroleum gas, industrial gases, and real estate and memorial park operations. Minimal changes to the Issuer's financial condition will be expected after the transaction.
Other Relevant Information
This amendment is being made to correct the contents of the attachment herein, particularly with regard to the inclusion of the actual press release. The SEC 17-C (Current Report) and the necessary Secretary's Certificates will be submitted to the Commission and PSE together with the corresponding Press Release.